DIAZOXIDE
(Proglycem)Standard Prescription
diazoxide__mg PO Q__H (__mg/kg/24hr)
Dosages
Hyperinsulinemic hypoglycemia:
Infants: 1.6-5 mg/kg/dose PO Q8H (5-15 mg/kg/24 h)
Children: 1-2.5 mg/kg/dose PO Q8H OR 1.5-4 mg/kg/dose PO Q12H (3-8 mg/kg/24 hr)
Infants: 1.6-5 mg/kg/dose PO Q8H (5-15 mg/kg/24 h)
Children: 1-2.5 mg/kg/dose PO Q8H OR 1.5-4 mg/kg/dose PO Q12H (3-8 mg/kg/24 hr)
Mechanism of Action
Antihypoglycemic. Inhibits the secretion of insulin by opening ATP-sensitive potassium channel of beta cells of the pancreas.
Forms Supplied
capsule: 100 mg (not stocked at BCCH)
liquid (BCCH): 50 mg/mL oral suspension.
50 mg/mL suspension can be obtained through the Health Canada Special Access Program (longer stability than BCCH compounded suspension).
liquid (BCCH): 50 mg/mL oral suspension.
50 mg/mL suspension can be obtained through the Health Canada Special Access Program (longer stability than BCCH compounded suspension).
Comments
Adverse effects include: heart failure from salt and water retention, hyperglycemia, hyperuricemia, hypertrichosis.
Consider adding hydrochlorothiazide.
IV dosage form was discontinued by the manufacturer in 2003.
Consultation with Endocrinology before starting is recommended.
Renal impairment: consider decreased dose.
Caution in neonates with hyperbilirubinemia.
Consider adding hydrochlorothiazide.
IV dosage form was discontinued by the manufacturer in 2003.
Consultation with Endocrinology before starting is recommended.
Renal impairment: consider decreased dose.
Caution in neonates with hyperbilirubinemia.
References
1, 44, 209, 533
Last Edited
2021-12-04 06:35:13